Profusa, Inc.(PFSA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.1M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PFSA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Profusa, Inc. (PFSA), a Healthcare sector company. PFSA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), Profusa, Inc. reports net income of $-3.5M, free cash flow of $-2.6M. Top institutional holders of PFSA by reported 13-F value include CITADEL ADVISORS, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. PFSA trades on the Nasdaq exchange and files with the SEC under CIK 1859807. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PFSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Profusa, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-3.5M
Free Cash Flow
Q1 2026
$-2.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
Operating Income
EPS (Diluted)
Total Assets
-94.4% YoYTotal Debt
Op. Cash Flow
| Metric | FY 2023 | FY 2021 |
|---|---|---|
| Net Income | $1.2M | — |
| Operating Income | $-1.5M | — |
| EPS (Diluted) | $0.12 | — |
| Total Assets | $10.9M -94.4% | $193.1M |
| Total Debt | $200.0K | — |
| Operating Cash Flow | $-2.1M | — |
AI Insight: PFSA Financial Trends
Profusa remains pre-revenue with accelerating operating losses and deteriorating cash burn, signaling extended cash runway pressure.
• Operating losses widened to $23M in Q3 2025 from $1M in Q2 2025, then moderated to $4M in Q1 2026.
• Operating cash flow deteriorated sharply to $11M outflow in Q3 2025; remained negative at $3M–$5M in subsequent quarters.
• No reported revenue through Q1 2026; company remains pre-commercial after 9+ quarters of data.
⚠ Equity has swung from $119M deficit (Q4 2024) to $27M deficit (Q1 2026); cumulative losses eroding shareholder value.
⚠ Quarterly net losses averaged $7M in 2025; Q3 spike to $18M suggests acceleration in R&D or operational spend.
AI Insight: PFSA Ratio Trends
Data too sparse to identify meaningful trends — only two ROA observations available across nine quarters.
• ROA swung from -18.5% in Q2 2024 to 4.2% in Q3 2024, indicating sharp sequential improvement in asset efficiency.
⚠ All other profitability and leverage ratios missing from Q4 2024 onward — unable to assess recent operational or balance-sheet health.
Get alerted when PFSA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Profusa, Inc. including:
Top Institutional Holders of PFSA
CITADEL ADVISORS LLC
$15.6K30,844 shGEODE CAPITAL MANAGEMENT, LLC
$15.6K30,721 shVANGUARD CAPITAL MANAGEMENT LLC
$2.0K3,939 shTower Research Capital LLC (TRC)
$908.001,791 shVANGUARD FIDUCIARY TRUST CO
$859.001,694 shMORGAN STANLEY
$811.001,600 shUBS Group AG
$337.00665 shSBI Securities Co., Ltd.
$23.0045 shFMR LLC
$7.0013 shMint Tower Capital Management B.V.
$0.00125 sh
| Fund | Value | Shares |
|---|---|---|
| CITADEL ADVISORS LLC | $15.6K | 30,844 |
| GEODE CAPITAL MANAGEMENT, LLC | $15.6K | 30,721 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.0K | 3,939 |
| Tower Research Capital LLC (TRC) | $908.00 | 1,791 |
| VANGUARD FIDUCIARY TRUST CO | $859.00 | 1,694 |
| MORGAN STANLEY | $811.00 | 1,600 |
| UBS Group AG | $337.00 | 665 |
| SBI Securities Co., Ltd. | $23.00 | 45 |
| FMR LLC | $7.00 | 13 |
| Mint Tower Capital Management B.V. | $0.00 | 125 |
More Healthcare Companies
View all Healthcare →Put PFSA on your watchlist
Track score changes the day Profusa, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PFSA a good stock to buy?
13F Pro's AI-powered analysis of Profusa, Inc. (PFSA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PFSA are available on the PFSA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PFSA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PFSA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Profusa, Inc.'s investment landscape.